Labcorp trades in line with intrinsic value after two deals
Alpha Vantage · Simply Wall Street · · AI-summarised by FinFlash
A discounted cash flow model suggests Labcorp Holdings is valued broadly in line with its intrinsic value, implying the acquisitions of Myriad Genetics' Prenatal Health testing business and BioReference Health assets are already reflected in its cash generation. The stock has returned 65.9% over three years.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.